Ovid Therapeutics (OVID) Net Margin (2020 - 2025)
Ovid Therapeutics filings provide 6 years of Net Margin readings, the most recent being 1345.82% for Q4 2025.
- Quarterly Net Margin rose 1352082.0% to 1345.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 339.33% through Mar 2026, up 421779.0% year-over-year, with the annual reading at 240.13% for FY2025, 443001.0% up from the prior year.
- Net Margin hit 1345.82% in Q4 2025 for Ovid Therapeutics, up from 9210.61% in the prior quarter.
- Across five years, Net Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.33% in Q3 2022.
- Average Net Margin over 5 years is 14450.0%, with a median of 8653.28% recorded in 2024.
- Peak annual rise in Net Margin hit 9747448bps in 2023, while the deepest fall reached -1844658bps in 2023.
- Ovid Therapeutics' Net Margin stood at 84.46% in 2021, then tumbled by -29532bps to 24859.09% in 2022, then surged by 57bps to 10790.14% in 2023, then decreased by -13bps to 12175.0% in 2024, then surged by 111bps to 1345.82% in 2025.
- Per Business Quant, the three most recent readings for OVID's Net Margin are 1345.82% (Q4 2025), 9210.61% (Q3 2025), and 74.68% (Q2 2025).